Anderson MA (2013): Targeting Bcl-2 in the treatment of leukemia and lymphoma

Mary Ann Anderson, MBBS, PhD, Talks Emerging BCL2 Inhibitors in CLL at SOHO 2023Подробнее

Targeting apoptosis - developing drugs to inhibit Bcl-2 and Mcl-1Подробнее

Targeting BCL-2 in MDSПодробнее

CLL: The Current and Future Paradigms of BCL2 InhibitionПодробнее

Dr. Ken Anderson and the impact LLS has on his researchПодробнее

BCL-2 targeting in AML: updatesПодробнее

Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphomaПодробнее

Importance of Bcl-2-targeted therapiesПодробнее

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaПодробнее

Treating AML with BCL-2 inhibitorsПодробнее

Targeting BCL-2 in Acute Myeloid LeukemiaПодробнее

AML On The Go - BCL-2 Inhibition in Acute Myeloid LeukemiaПодробнее

BCL2 Inhibition in CLL: Managing Toxicity and AdministrationПодробнее

Is Finite-Duration Therapy the New Frontline Standard of Care for CLL?Подробнее

Update on Venetoclax for CLLПодробнее

ABT-263 (Navitoclax): A Targeted Drug Offering New Hope in Cancer Treatment | GlpBioПодробнее

Advances in BTK and BCL2 inhibitors for CLLПодробнее

B-cell lymphoma treatment & research | MD Anderson Moon Shots ProgramПодробнее

Professor David Vaux: BCL-2, cell death and cancer researchПодробнее